Gaboxadol
Gaboxadol (pronounced ga-box-a-dol), also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP), is a conformational isomer of musimol. It was originally developed by the Danish pharmaceutical company H. Lundbeck A/S and later acquired by Merck & Co. for development as a potential treatment for insomnia and other sleep disorders.
Etymology
The name Gaboxadol is derived from its chemical structure, which is a combination of a gabaminergic compound and an oxadiazole ring. The suffix "-ol" indicates the presence of an alcohol group in the molecule.
Pharmacology
Gaboxadol is a GABA agonist, specifically at the GABAAδ receptor. It is unique in its ability to promote sleep at doses that do not impair cognition. This is in contrast to most other available sleep aids, which often have significant cognitive side effects.
Clinical Trials
Gaboxadol has undergone Phase II and III clinical trials for the treatment of insomnia. However, it was discontinued from development due to concerns about its safety profile.
Related Terms
See Also
External links
- Medical encyclopedia article on Gaboxadol
- Wikipedia's article - Gaboxadol
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski